Vaccinex, Inc. Announces Intermin Response Data from KEYNOTE Study
Vaccinex, Inc. (Nasdaq: VCNX) reported its interim response data in the Phase Ib segment of the KEYNOTE-B84 study earlier today. Results from Study The KEYNOTE-B84 study of the Company's pepinemab in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients...